I n individuals with cognitive impairment (CI), most clinical and epidemiological studies show that depression increases the risk of developing dementia. 1 In patients with both depression and cognitive impairment (DEP-CI), the conventional expectation is that successful treatment of depression leads to cognitive improvement. However, elderly patients with DEP-CI often do not show cognitive improvement with antidepressant treatment, 2, 3 and have a high rate of transitioning to dementia.
In DEP-CI patients treated with antidepressants, we previously reported an improvement in episodic verbal memory with the cholinesterase inhibitor (CheI) donepezil in a 12-week placebo-controlled pilot trial. 2 Olfactory identification deficits are known to predict the transition from mild cognitive impairment (MCI) to Alzheimer's Disease (AD). 4 Muscarinic cholinergic transmission plays a major role in odor identification, and there is initial evidence that improvement in odor identification is associated with clinical improvement in patients with AD who receive CheI. 5 In this pilot report, we explored the impact of olfactory identification as a secondary predictive measure from the previously published efficacy study on treatment response to donepezil in DEP-CI patients. 2 
METHODS
Outpatients were recruited from the Late Life Depression Clinic and Memory Disorders Center at the New York State Psychiatric Institute. The study was IRB approved and conducted in accord with the Helsinki Declaration of 1975. Written informed consent was obtained before study entry.
Eligibility Criteria
Patient inclusion criteria were age 55 to 80 years, subjective cognitive complaints, CIr10 years by history, Folstein Mini Mental State Exam (MMSE) score >20/30, major depressive disorder or dysthymic disorder by DSM-IV criteria, and a 24-item Hamilton Rating Scale for Depression (HRSD-24)Z14. Neuropsychological inclusion criteria required MMSE recall score r2/3 objects at 5 minutes and/or impaired performance >1 SD below standardized norms on at least 2 tests or >1.5 SD below standardized norms on at least 1 test on a brief neuropsychological test (NPT) battery. The NPT battery comprised the Selective Reminding Test (targeting memory), WAIS-III digit symbol and Trailmaking B (executive function), CFL-version of the Controlled Oral Word Association Test (COWAT-CFL)(verbal fluency), and Trailmaking A (attention/psychomotor speed). 2 Exclusion criteria were other DSM-IV Axis 1 psychiatric disorders, dementia, unstable acute medical condition, specific neurological disorder (eg, stroke, Parkinson's disease), and anosmia (University of Pennsylvania Smell Identification Test, UPSITr12/40). 6 In brief, this study sample comprised patients with depression and CI without a clinical diagnosis of dementia.
Procedures
Odor identification was assessed using the UPSIT, which uses 40 scratch and sniff multiple choice format items with the total score ranging from 0 to 40. 7 After neurological and psychiatric examination and routine baseline laboratory tests, the UPSIT was administered at baseline.
The NPT battery was administered at baseline, 8 weeks, 20 weeks, and at study exit if it occurred before 20 weeks. The primary outcome measure, selected a priori, was the Selective Reminding Test total immediate recall score (SRT-tot). The HRSD-24 and the Clinical Global Impression-Severity scale were used to monitor depression.
After baseline testing, sertraline was prescribed with an alternative doctor's choice antidepressant for patients previously intolerant/unresponsive to sertraline. Medication dose was titrated in a stepwise manner over the first 4 weeks based on efficacy and side effects. The randomized, double-blind, placebo-controlled, add-on donepezil phase was initiated at week 8 for all patients with persistent subjective cognitive complaints or NPT scores >1 SD below standardized norms on any test at the 8-week timepoint. Donepezil or placebo in identical-looking tablets was dispensed at 5 mg/d for the first 4 weeks and was increased to 10 mg for the remainder of the trial, with additional dose-adjustment based on side effects.
Statistical Analyses
Baseline demographic and clinical measures were compared between the donepezil (n = 11) and placebo (n = 7) groups by using t test and w 2 for continuous and categorical variables, respectively.
Intent-to-treat analyses (last observation carried forward) were conducted. The treatment groups (donepezil or placebo) were compared with ANCOVA on SRT-tot scores as the dependent variable. UPSIT scores were analyzed as continuous variables and also dichotomized (median split <30 vs. Z30) for clinically relevant analyses. All analyses were 2-tailed with alpha <0.1 for significance because this was a pilot trial with small sample size.
RESULTS
Two patients dropped out before entering the doubleblind placebo-controlled donepezil trial. Anosmia based on the initial test performance (score < 12) led to exclusion of 2 additional patients from the data analysis. Therefore, of 22 patients who started the study, 18 patients were included in analyses. No treatment group differences were noted in baseline demographics and UPSIT scores, and measures of depression and cognition at week 8 ( Table 1 ). The mean baseline UPSIT score of 28 was similar to that previously reported in patients with MCI. 4 The reported side effects measured by the Treatment Emergent Symptom Scale was similar in both the donepezil and placebo-treated patients. There were no significant correlations between the baseline UPSIT score and baseline or 8-week cognitive test scores (MMSE, SRT-tot, COWAT-CFL, Trailmaking A and B) or depressive symptom scores (HRSD-24).
ANCOVA with SRT-tot change score (8 to 20 wk) as the dependent variable showed a main effect of treatment group (donepezil vs. placebo, F 1,12 = 11.3, P = 0.006). SCID diagnosis (major depression or dysthymic disorder) (F 1,12 = 6.5, P = 0.02) and baseline UPSIT score (F 1,12 = 4.6, P = 0.05) were significant covariates. In similar analyses restricted to patients with major depression (n = 15), the effect of treatment group (F 1,10 = 9.4, P = 0.01) and baseline UPSIT score (F 1,10 = 3.72, P = 0.08) remained significant. In Pearson correlation analyses, baseline olfactory performance scores (UPSIT score) inversely correlated with improvement in SRT-tot score (8 to 20 wk) in the donepezil (r = À 0.56; P = 0.07) but not the placebo (r = À0.20; P = 0.6) group, indicating that worse olfactory performance was associated with better episodic verbal memory performance after 12 weeks on donepezil.
In additional analyses, the sample was dichotomized by the median UPSIT score (low < 30 vs. high Z30). In a 2-way ANOVA using SRT-tot change score (8 to 20 wk) as the dependent variable and treatment group (donepezil or placebo) and dichotomized UPSIT scores as between-subject variables, both treatment group (F 1,14 = 4.6, P = 0.05) and baseline olfactory performance (F 1,14 = 3.4, P = 0.09) were associated with the improvement in SRT-tot score. In the donepezil group with low UPSIT scores, there was a mean (SD) increase of 10.4 (11.4) points (44% improvement) in SRT-tot scores after donepezil treatment compared with 2.7 (8.4) points (11% improvement) in those with high UPSIT scores. In patients on placebo, there was a mean increase of 1.25 (9.7) points (8% improvement) in patients with low UPSIT scores and a mean 7.3 (2.1) decrease (16% worsening) in patients with high UPSIT scores (Fig. 1) . In a post hoc t test that compared patients who received donepezil and had low UPSIT scores (n = 5) to the rest of the sample (n = 13), there was significant improvement in SRT-tot scores in the donepezil group with low UPSIT scores compared with the rest of the sample (t = 2.15, P < 0.05).
DISCUSSION
The findings indicate that olfactory identification deficits represent a potential biomarker to predict response to CheI treatment in patients with DEP-CI. Olfactory deficits are an indicator of underlying AD brain pathology, and potentially can be useful to predict improvement with CheI not only in patients with DEP-CI but possibly in patients with MCI and mild AD.
CheIs increase muscarinic cholinergic neurotransmission in the brain, and muscarinic cholinergic receptors play a prominent role in the olfactory pathway. 5, 8, 9 Further, intranasal atropine, a muscarinic antagonist, when administered to human subjects is associated with a reduction of odor identification test performance in patients at high risk of developing AD. 9 In another study, patients with mild to moderate AD showed an initial improvement in UPSIT scores with donepezil treatment over 12 weeks that was associated with global ratings of improvement over 3 months. 8 These lines of evidence support the potential utility of odor identification deficits, which reflect impairment in muscarinic cholinergic neurotransmission, in the prediction of cognitive improvement with CheI treatment.
The main limitation to this study is small sample size. If the finding of olfactory identification deficits predicting CheI response is replicated in larger samples, utilizing this simple, reliable, and relatively inexpensive approach 7 may improve the selection of patients to receive CheI clinically and help avoid unnecessary exposure to CheI in patients unlikely to benefit and/or develop side effects. Odor identification tests may also prove useful in clinical trials of other types of agents in MCI and AD, because the presence of olfactory deficits is an indicator of underlying AD brain pathology and the severity of olfactory deficits is related to the severity of cognitive deficits and dementia. 10 
